Stopping maintenance treatment in multiple myeloma patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at whether it is safe to stop “maintenance” treatment for people with multiple myeloma who have been in remission for a long time, including those who stopped early because of side effects. It tests whether stopping therapy affects disease control and helps reduce ongoing treatment burden.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with multiple myeloma and are in first-line treatment (not later treatment rounds)
- You have had maintenance therapy for at least 2 years, or you stopped it early because of side effects and still have sustained MRD-negative complete remission
- You can understand the study and sign consent, and you agree to follow the study visit schedule (but you can stop anytime without losing other care)
- You have not had an organ transplant, and you do not need medicines that strongly suppress the immune system
- You have not had an allogeneic stem cell transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study looks at whether it’s safe to stop the usual “maintenance” medicine after a strong response in multiple myeloma. It aims to see if stopping treatment for people with very low remaining disease reduces drug exposure without allowing relapse too soon.
This study looks at whether people with newly diagnosed multiple myeloma can safely continue or adjust treatment after they reach “MRD-negative,” meaning very low signs of disease in the bone marrow. It may help reduce the chance of relapse while avoiding unnecessary treatment for some patients.
This study checks on the long-term safety and how well the body handles the GC012F treatment over time. For people who already had this treatment before, it helps doctors see if the effects last and if there are any late side effects.
This trial compares stopping treatment after a set number of cycles versus continuing it for people over 65 or those who cannot have a stem cell transplant. It tests whether a fixed treatment period works as well as long-term treatment for newly diagnosed multiple myeloma.
This trial tests two treatments (lenalidomide plus elranatamab versus lenalidomide plus daratumumab) as maintenance therapy after a stem cell transplant for multiple myeloma. The goal is to see which combination is better at keeping the cancer in remission.
This trial tests a personalized approach to maintenance therapy for people with multiple myeloma who have already had a stem cell transplant. Your treatment plan may be adjusted based on how well your cancer responds and on certain risk factors, with the goal of keeping you in remission longer.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.